Sermorelin does something measurable, and it is not the thing most people buy it for. It makes your pituitary release more of your own growth hormone, which is well established. What that release does to your body, your sleep and your energy is a much shorter story than the marketing suggests. One placebo-controlled trial in nineteen adults, from 1997, never repeated.
This page walks the chain link by link and marks where each one was measured. If you are choosing between sellers rather than deciding whether to start, the injection board has the pricing; this is the question to answer first.
What sermorelin actually is
Sermorelin is a synthetic copy of the first 29 amino acids of growth-hormone-releasing hormone — the fragment that carries the biological activity. It does not supply growth hormone. It binds the GHRH receptor on the pituitary and asks the gland to release more of yours. That is a genuinely different pharmacology from injecting GH itself — and the basis for every claim made about it.
The mechanism holds up under sustained use, which is not a given for drugs that work by stimulation. In eight short, slowly growing children given continuous subcutaneous GHRH(1-29) for up to a year, 24-hour profiles showed sustained augmentation of pulsatile GH secretion without evidence of desensitization. The pituitary’s response to a supramaximal test dose also remained constant across treatment [1]. Growth velocity rose from 4.6 to 7.0 cm/year in the five children treated a full year (p = 0.04). Small, uncontrolled for that endpoint, and real.
In adults, nightly dosing at 10 micrograms per kilogram produced a GH pulse within 10 minutes lasting about two hours, sustained across five months. 12-hour integrated nocturnal GH rose significantly against placebo in both sexes (women p < 0.01, men p < 0.05), and IGF-I and IGFBP-3 climbed within two weeks [2]. So: the hormone moves. That part is not in dispute.
The one adult outcome trial, in full
Everything a buyer actually wants to know rests on a single study. It is worth reading in detail, because the details are where it stops supporting the pitch.
Nineteen adults aged 55 to 71, ten women and nine men, single-blind, randomized, placebo-controlled, five months [2]. The findings, quoted from the abstract: treatment “resulted in a significant increase in skin thickness (P < 0.05) in both genders and increased lean body mass in men only (P < 0.05), with no other changes in body composition or bone mineral density in either gender.” On quality of life, there was “a significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in men, but not in women, and sleep quality was unaffected in both genders.”
Read that twice if you came here from a marketing page. The lean-mass result is real and it is the strongest thing anyone can say for this drug. It was also men only, in nineteen people, twenty-nine years ago, and nobody has replicated it since. Sleep — the single most commonly advertised benefit — did not move in either sex. Bone density did not move. Women saw nothing on any body-composition or quality-of-life measure the trial tested. That is why our board for women leads with this trial rather than with a seller.
A companion paper on the same cohort reported GH and IGF-1 rises of up to 107% and 28% alongside immune-marker changes, and no adverse effects [3].
What happened when it was tested against a real comparator
One trial put a GHRH analog against actual growth hormone on an actual outcome, in the population most likely to respond. Sixty growth-hormone-deficient children were randomized to GHRH(1-29) at 30 µg/kg/day, the same at 60 µg/kg/day, or GH at 0.1 IU/kg/day, for six months. Mean height velocities were 9.2, 9.3 and 14.6 cm/year respectively, p < 0.01 [4].
Two things fall out of those three numbers. Real GH beat the analog decisively on the endpoint that mattered. And doubling the analog dose — 30 to 60 µg/kg — bought nothing at all, which is worth holding onto when a seller offers you a higher-dose tier. The same trial found 39 of 40 analog-treated children developed anti-GHRH antibodies, with no correlation to height gained and near-complete disappearance nine months after stopping.
A separate uncontrolled series in seven significantly short children, dosed 30 µg/kg/day for up to 24 months, was explicitly designed to discontinue non-responders [5]. That design inflates apparent efficacy in whoever is left at the end — a reminder of how thin the ground is under the pediatric claims too.
What we searched, and when
In September 2026 we queried PubMed for everything indexed under sermorelin. The drug has 332 records in total, most of them 1980s and 1990s pediatric endocrinology or later doping-detection chemistry. Restricted to randomized trials, the count is ten records, ever. A search for body composition, lean mass or strength returned six, of which exactly one is a human outcome trial — the 1997 study above. A search for sleep returned eight, none of them a positive human sleep-outcome trial. As a known-good control, a randomized-trial query for metformin on the same pipeline returned 2,139 records, so the database was reachable and the query shape works.
That census is the finding. It is not that sermorelin has been tested and failed. It is that it has barely been tested in adults at all — and the marketing has run far ahead of what anyone measured.
The comparison that makes the gap obvious
Tesamorelin is the same drug class — a GHRH analog — and it is currently FDA-approved and marketed, unlike sermorelin’s discontinued brand. It also has the outcome trials sermorelin does not. In 60 obese adults over 12 months at 2 mg/day, visceral adipose tissue changed by −16 ± 9 cm² against +19 ± 9 cm² on placebo, a treatment effect of −35 cm² (95% CI −58 to −12), p = 0.003. The same trial found significant improvements in carotid intima-media thickness (p = 0.02), CRP (p = 0.04) and triglycerides (p = 0.02) [6]. In 152 adults over 20 weeks at 1 mg/day, cognition improved on an intent-to-treat basis (p = .03), with executive function at p = .005 [7]. Still, 68% of the treated arm reported adverse events against 36% on placebo.
Those are modern, adequately powered trials with real endpoints. They are not evidence for sermorelin. They are evidence that this drug class can be studied properly, and that sermorelin has not been.
Safety, and the cancer question people actually search
The adult trial reported that the “only adverse side-effect was transient hyperlipidemia, which resolved by the end of the study” [2], and the companion immune paper reported no adverse effects [3]. The pediatric comparison recorded no serious side effects, with three children reporting mild injection-site irritation — alongside that 39-of-40 antibody rate [4].
“Sermorelin and cancer” is a heavily searched pairing and the literature under it is mostly about something else: 116 records, the large majority studying GHRH receptor antagonists as investigational cancer drugs. That is a pharmacologically opposite class, designed to block the signaling sermorelin stimulates. Two records bear on the question directly and neither is clinical. One found that native GHRH at 0.1 µM in cell culture increased proliferation and migration in a non-tumor human prostate epithelial line, with treated cells forming tumors in nude mice 49 days after injection [8]. That is preclinical work, using native GHRH rather than sermorelin, at a concentration and route that are not a clinical dose. The other, despite a title naming sermorelin as a potential glioma drug, is a purely computational screen across 1,018 patients’ expression data and 4,865 candidate compounds. In that screen, sermorelin was never given to a cell, an animal or a person [9].
The honest reading: no qualifying human clinical or epidemiological evidence links sermorelin therapy to increased cancer risk. There is also no long-term human surveillance data on sermorelin users to rule it out. “No signal found, but not well studied” is the accurate sentence. “Proven safe” is not.
The dose nobody tested
Every adult efficacy number on this page comes from 10 µg/kg nightly. Commercial anti-aging protocols commonly advertise 200 to 300 µg a night, flat, for everyone. That figure comes from clinical and commercial practice rather than from any published trial — and we found no dose-ranging study covering the commercial range. So the doses being sold sit above the doses that produced the only outcome data there is, with nothing published in between.
Combine that with how few sellers publish a dose at all, and the comparison problem becomes concrete: a cheaper month may simply be a smaller quantity — from the outside, those look identical. It is the first question to ask a seller, and a prescriber-led service is more likely to answer it than a checkout page.
So: does it work?
It raises your own growth hormone. That is established and repeatable. Beyond that, the honest answer is mixed. One small trial found more lean mass and better well-being in men, and nothing measurable in women. No trial has found a sleep benefit, and no trial has tested the doses being sold. The one head-to-head against real growth hormone went badly for the analog. Everything on the market is compounded and therefore not FDA-reviewed for safety, efficacy or quality.
None of that makes it a scam. It makes it an experiment you are paying for. The only version worth doing is the one where you know which parts are measured before you start.